Janux Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.40) Per Share, HC Wainwright Forecasts (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for shares of Janux Therapeutics in a research report issued on Monday, August 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.40) per share for the quarter, down from their prior forecast of ($0.37). HC Wainwright currently has a "Buy" rating and a $63.00 target price on the stock. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.21) EPS, Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($1.83) EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The business had revenue of $8.90 million during the quarter, compared to analysts' expectations of $0.77 million. Janux Therapeutics's revenue was up 709.1% compared to the same quarter last year.

JANX has been the subject of several other research reports. Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Wedbush reiterated an "outperform" rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $65.57.

Janux Therapeutics Stock Down 0.0 %

JANX traded down $0.02 on Wednesday, hitting $44.90. 340,200 shares of the company traded hands, compared to its average volume of 750,046. The company has a 50 day moving average of $41.27 and a 200-day moving average of $40.31. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The stock has a market capitalization of $2.33 billion, a PE ratio of -36.80 and a beta of 3.57.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the transaction, the insider now directly owns 3,271,216 shares in the company, valued at approximately $179,099,076. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the sale, the insider now owns 3,271,216 shares in the company, valued at approximately $179,099,076. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Tighe Reardon sold 822,721 shares of the firm's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the transaction, the chief financial officer now directly owns 633,673 shares of the company's stock, valued at approximately $34,693,596.75. The disclosure for this sale can be found here. Insiders sold 3,000,000 shares of company stock valued at $164,250,000 in the last ninety days. Corporate insiders own 35.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in Janux Therapeutics in the 2nd quarter valued at about $5,715,000. Blue Owl Capital Holdings LP purchased a new stake in Janux Therapeutics in the second quarter valued at approximately $1,676,000. The Manufacturers Life Insurance Company increased its position in Janux Therapeutics by 234.7% during the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company's stock worth $1,007,000 after purchasing an additional 16,864 shares during the last quarter. AQR Capital Management LLC purchased a new position in Janux Therapeutics during the second quarter worth approximately $215,000. Finally, Samlyn Capital LLC boosted its holdings in shares of Janux Therapeutics by 9.6% in the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company's stock valued at $13,602,000 after purchasing an additional 28,312 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.